FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384929069> ?p ?o ?g. }

• W4384929069 abstract "Immune checkpoint inhibitors (ICIs) are among the most notable advances in cancer immunotherapy; however, reliable biomarkers for the efficacy of ICIs are yet to be reported. Programmed death (PD)‑ligand 1 (L1)‑expressing CD14⁺ monocytes are associated with shorter overall survival (OS) time in patients with cancer treated with anti‑PD‑1 antibodies. The present study focused on the classification of monocytes into three subsets: Classical, intermediate and non‑classical. A total of 44 patients with different types of cancer treated with anti‑PD‑1 monotherapy (pembrolizumab or nivolumab) were enrolled in the present study. The percentage of each monocyte subset was investigated, and the percentage of cells expressing PD‑L1 or PD‑1 within each of the three subsets was further analyzed. Higher pretreatment classical monocyte percentages were correlated with shorter OS (r=‑0.32; P=0.032), whereas higher non‑classical monocyte percentages were correlated with a favorable OS (r=0.39; P=0.0083). PD‑L1‑expressing classical monocytes accounted for a higher percentage of the total monocytes than non‑classical monocytes with PD‑L1 expression. In patients with non‑small cell lung cancer (NSCLC), a higher percentage of PD‑L1‑expressing classical monocytes was correlated with shorter OS (r=‑0.60; P=0.012), which is similar to the observation for the whole patient cohort. Comparatively, higher percentages of non‑classical monocytes expressing PD‑L1 were significantly associated with better OS, especially in patients with NSCLC (r=0.60; P=0.010). Moreover, a higher percentage of non‑classical monocytes contributed to prolonged progression‑free survival in patients with NSCLC (r=0.50; P=0.042), with similar results for PD‑L1‑expressing non‑classical monocytes. The results suggested that the percentage of monocyte subsets in patients with cancer before anti‑PD‑1 monotherapy may predict the treatment efficacy and prognosis. Furthermore, more classical monocytes and fewer non‑classical monocytes, especially those expressing PD‑L1, are involved in shortening OS time, which may indicate the poor efficiency of anti‑PD‑1 treatment approaches." @default.
• W4384929069 created "2023-07-22" @default.
• W4384929069 creator A5000823360 @default.
• W4384929069 creator A5003210968 @default.
• W4384929069 creator A5004862046 @default.
• W4384929069 creator A5006214131 @default.
• W4384929069 creator A5019240223 @default.
• W4384929069 creator A5037570310 @default.
• W4384929069 creator A5040125996 @default.
• W4384929069 creator A5044453967 @default.
• W4384929069 creator A5045376146 @default.
• W4384929069 creator A5045832805 @default.
• W4384929069 creator A5048659704 @default.
• W4384929069 creator A5056826221 @default.
• W4384929069 creator A5064671011 @default.
• W4384929069 creator A5066387673 @default.
• W4384929069 creator A5070373933 @default.
• W4384929069 creator A5070396112 @default.
• W4384929069 creator A5071061939 @default.
• W4384929069 creator A5073461841 @default.
• W4384929069 creator A5076309217 @default.
• W4384929069 creator A5076349434 @default.
• W4384929069 creator A5078365630 @default.
• W4384929069 creator A5080960856 @default.
• W4384929069 creator A5082653503 @default.
• W4384929069 creator A5089439324 @default.
• W4384929069 date "2023-07-20" @default.
• W4384929069 modified "2023-09-27" @default.
• W4384929069 title "Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy" @default.
• W4384929069 cites W1927075449 @default.
• W4384929069 cites W1963904011 @default.
• W4384929069 cites W1984378291 @default.
• W4384929069 cites W1996213381 @default.
• W4384929069 cites W2004238073 @default.
• W4384929069 cites W2019607817 @default.
• W4384929069 cites W2019648143 @default.
• W4384929069 cites W2029726426 @default.
• W4384929069 cites W2037338605 @default.
• W4384929069 cites W2073110901 @default.
• W4384929069 cites W2089573422 @default.
• W4384929069 cites W2092617134 @default.
• W4384929069 cites W2104347254 @default.
• W4384929069 cites W2107551122 @default.
• W4384929069 cites W2142242761 @default.
• W4384929069 cites W2159803625 @default.
• W4384929069 cites W2166035732 @default.
• W4384929069 cites W2166760323 @default.
• W4384929069 cites W2465821684 @default.
• W4384929069 cites W2527905628 @default.
• W4384929069 cites W2529896336 @default.
• W4384929069 cites W2537934149 @default.
• W4384929069 cites W2542285312 @default.
• W4384929069 cites W2557730509 @default.
• W4384929069 cites W2560827811 @default.
• W4384929069 cites W2572174216 @default.
• W4384929069 cites W2745335283 @default.
• W4384929069 cites W2769728123 @default.
• W4384929069 cites W2789563811 @default.
• W4384929069 cites W2794577178 @default.
• W4384929069 cites W2807646229 @default.
• W4384929069 cites W2811118866 @default.
• W4384929069 cites W2884883038 @default.
• W4384929069 cites W2891760302 @default.
• W4384929069 cites W2897381777 @default.
• W4384929069 cites W2912810891 @default.
• W4384929069 cites W2916964158 @default.
• W4384929069 cites W2949413254 @default.
• W4384929069 cites W2972873235 @default.
• W4384929069 cites W3010839046 @default.
• W4384929069 cites W3015178699 @default.
• W4384929069 cites W3033530735 @default.
• W4384929069 cites W3033847468 @default.
• W4384929069 cites W3037642373 @default.
• W4384929069 cites W3038041373 @default.
• W4384929069 cites W3047580238 @default.
• W4384929069 cites W3085714880 @default.
• W4384929069 cites W3092987674 @default.
• W4384929069 cites W3118950316 @default.
• W4384929069 cites W3119994181 @default.
• W4384929069 cites W3132958914 @default.
• W4384929069 cites W3134794896 @default.
• W4384929069 cites W3197935357 @default.
• W4384929069 cites W3212602671 @default.
• W4384929069 cites W4200092823 @default.
• W4384929069 cites W4224078757 @default.
• W4384929069 cites W4288430372 @default.
• W4384929069 cites W4309212964 @default.
• W4384929069 doi "https://doi.org/10.3892/ol.2023.13967" @default.
• W4384929069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37559573" @default.
• W4384929069 hasPublicationYear "2023" @default.
• W4384929069 type Work @default.
• W4384929069 citedByCount "0" @default.
• W4384929069 crossrefType "journal-article" @default.
• W4384929069 hasAuthorship W4384929069A5000823360 @default.
• W4384929069 hasAuthorship W4384929069A5003210968 @default.
• W4384929069 hasAuthorship W4384929069A5004862046 @default.
• W4384929069 hasAuthorship W4384929069A5006214131 @default.
• W4384929069 hasAuthorship W4384929069A5019240223 @default.
• W4384929069 hasAuthorship W4384929069A5037570310 @default.
• W4384929069 hasAuthorship W4384929069A5040125996 @default.

• next